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AbstrACt
Introduction Accidental urine leakage is a distressing 
problem that affects around one in three women. The 
main types of urinary incontinence (UI) are stress, urgency 
and mixed, with stress being most common. Current UK 
guidelines recommend that women with UI are offered at 
least 3 months of pelvic floor muscle training (PFMT). There 
is evidence that PFMT is effective in treating UI, however 
it is not clear how intensively women have to exercise to 
give the maximum sustained improvement in symptoms, 
and how we enable women to achieve this. Biofeedback is 
an adjunct to PFMT that may help women exercise more 
intensively for longer, and thus may improve continence 
outcomes when compared with PFMT alone. A Cochrane 
review was inconclusive about the benefit of biofeedback, 
indicating the need for further evidence.
Methods and analysis This multicentre randomised 
controlled trial will compare the effectiveness and cost-
effectiveness of PFMT versus biofeedback-mediated 
PFMT for women with stress UI or mixed UI. The primary 
outcome is UI severity at 24 months after randomisation. 
The primary economic outcome measure is incremental 
cost per quality-adjusted life-year at 24 months. Six 
hundred women from UK community, outpatient and 
primary care settings will be randomised and followed up 
via questionnaires, diaries and pelvic floor assessment. 
All participants are offered six PFMT appointments over 
16 weeks. The use of clinic and home biofeedback is 
added to PFMT for participants in the biofeedback group. 
Group allocation could not be masked from participants 
and healthcare staff. An intention-to-treat analysis of 
the primary outcome will estimate the mean difference 
between the trial groups at 24 months using a general 
linear mixed model adjusting for minimisation covariates 
and other important prognostic covariates, including the 
baseline score.
Ethics and dissemination Approval granted by the 
West of Scotland Research Ethics Committee 4 (16/
LO/0990). Written informed consent will be obtained from 
participants by the local research team. Serious adverse 
events will be reported to the data monitoring and ethics 
committee, the ethics committee and trial centres as 
required. A Standard Protocol Items: Recommendations for 
Interventional Trials checklist and figure are available for 
this protocol. The results will be published in international 
journals and included in the relevant Cochrane review.
trial registration number ISRCTN 57746448; Pre-
results.
IntroduCtIon 
Urinary incontinence (UI), defined as any 
involuntary loss of urine,1 is a common 
condition in women. The prevalence of UI 
depends on the definition: using a broad 
definition, a range of between 5% and 69% 
strengths and limitations of this study
 ► The intervention being evaluated is highly relevant 
to UK National Health Service practice.
 ► The primary outcome measure is woman-centred, 
focusing on the severity of their urine leakage symp-
toms and the impact on their quality of life.
 ► An extensive longitudinal qualitative case study 
and process evaluation will provide rich data about 
women’s experiences of the intervention.
 ► All trial participants receive a high standard of 
pelvic floor muscle training, therefore the effect of 
adding biofeedback will need to be large to show 
between-group differences.
 ► Women randomised to the pelvic floor muscle train-
ing group could potentially access biofeedback, as 
devices are available to buy.
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is reported, with most studies in the range 25% to 45%.1 
The main types of UI are stress, urgency and mixed, 
with stress being most prevalent (accounts for around 
half of all UI), followed by mixed UI (stress and urgency 
combined) (most studies report 7.5%–25%) and fewer 
having urgency UI alone (most studies report 1%–7%). 
The cost to the UK National Health Service (NHS) annu-
ally of treating clinically significant UI in women was esti-
mated in the Leicestershire MRC Incontinence Study2 as 
£233million, not including the personal costs borne by 
the women which were estimated to be £178million in 
the same study.3 UI significantly impacts on daily living 
for the majority of women, with an associated increased 
prevalence of major depression.4 Among older women, 
social isolation, psychological distress5 and increased 
risk of admission to long-term care institutions6 feature 
highly. Thus UI is prevalent and costly to women, the 
NHS and society both financially and in terms of physical 
and mental well-being.
Currently, supervised pelvic floor muscle training 
(PFMT) of at least 3 months’ duration is the first-line 
treatment for stress and mixed UI.7 PFMT involves the 
regular practice of repeated voluntary pelvic floor muscle 
contractions, with sufficient exercise progression, in 
order to produce a training effect on the muscles. The 
aim of a PFMT programme is to increase the strength of 
the muscles, to build up muscle volume and thus improve 
structural support; to increase contraction endurance; to 
improve muscle resting tone; to improve muscle recruit-
ment through improved nerve function and properties 
of muscle fibres and improve cognitive awareness of body 
posture and a relaxed versus an unrelaxed state of the 
pelvic floor. In addition, a PFMT programme involves 
instruction on contracting and relaxing the pelvic floor 
muscles to improve coordination and functional use 
(termed the ‘Knack’) to occlude the urethra during 
physical activities that increase abdominal pressure and 
precipitate UI. Pelvic floor muscle contraction can also 
be used to inhibit a bladder contraction at the time of 
urgency as a method of urge suppression.
To produce improvements in muscle strength and 
endurance, the basic physiological principles must be 
adhered to8: overload (muscles need to perform more 
work than usual to the point of fatigue), specificity 
(muscles must be trained with exercise or physical activity 
that replicates as closely as possible the functional move-
ment required), maintenance and reversibility (benefits 
of the exercise will reverse if they are not undertaken on a 
regular basis). There is evidence to suggest that for effec-
tive resistance training in skeletal muscles in adults, two 
to four sets of 8–12 slow to moderate velocity, moderate to 
maximal intensity contractions be performed per day, 2–3 
days per week with progression over 16 weeks.9 10
Biofeedback is commonly used as an adjunct to PFMT. 
Biofeedback is the technique by which information about 
a normally unconscious physiological process is presented 
to the patient and/or the therapist as a visual, auditory or 
tactile signal.11 Electromyography (EMG) is the study of 
minute electrical potentials produced by depolarisation 
of muscle membrane.12 In EMG biofeedback, electrical 
activity arising from muscle activity (during exercise and 
voluntary effort) is recorded in microvolts and displayed 
as a visual or auditory signal for both patient and therapist 
to view. Within a PFMT programme, an internal vaginal 
probe is used to record electrical information from pelvic 
floor muscles through surface recordings. The probe is 
connected by cables to a biofeedback unit. Handheld 
units with a small visual display screen are available for 
home use. The display provides a visual representation 
of the muscles contracting and relaxing, allowing moni-
toring of strength, endurance and repetitions. The effec-
tiveness of using biofeedback to augment PFMT for UI 
in women has been the subject of a Cochrane review, the 
conclusions of which were that women who had PFMT 
including biofeedback were more likely to report cure or 
improvement of UI than those who had PFMT without 
biofeedback, but this finding was potentially confounded 
by more health professional contact and supervised treat-
ment time in the biofeedback groups.13 Biofeedback in 
general is considered an evidence-based behaviour change 
technique (BCT) according to the BCT taxonomy.14
The effect of PFMT relies first on sufficient exercise 
being undertaken for a long enough period to strengthen 
and hypertrophy the muscles, and second the continua-
tion of sufficient exercise so that strength is maintained.15 
Thus to intensify PFMT, adherence must be maximised 
both initially (ie, uptake or adoption of the exercise 
programme) and then continued over the longer-term 
(maintenance). Based on current evidence, it is not clear 
if the apparent benefit of biofeedback can be attributed 
to the biofeedback or to some other variable such as more 
health professional contact in those women receiving 
biofeedback.13 16 A common problem in previous trials 
was the failure to clearly state the purpose of biofeed-
back, or to describe the intervention protocol.13 Thus, it 
was not clear if the way the biofeedback was used could 
theoretically or in practice qualitatively change the inten-
sity or effectiveness of the PFMT. In our trial, the purpose 
of biofeedback is twofold: to enhance uptake initially as 
women will know they are performing the correct tech-
nique, and to support ongoing exercise training adher-
ence over the longer-term.
The aim of this trial is to determine the effectiveness 
and cost-effectiveness of PFMT compared with biofeed-
back-mediated PFMT for the treatment of stress or mixed 
UI. Both trial groups will have the same PFMT programme 
and same amount of health professional contact to estab-
lish if the addition of biofeedback improves incontinence 
outcomes.
MEthods And AnAlysIs
This trial design is a parallel group multicentre 
randomised controlled trial, comparing effectiveness and 
cost-effectiveness of PFMT versus biofeedback-mediated 
PFMT for women with stress or mixed UI. It is set in UK 
 o
n
 2 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024153 on 8 February 2019. Downloaded from 
3Hagen S, et al. BMJ Open 2019;9:e024153. doi:10.1136/bmjopen-2018-024153
Open access
community, outpatient and primary care settings, where 
continence care is usually provided. The trial includes 
a nested longitudinal qualitative case study and process 
evaluation (figure 1). The trial is assessing superiority of 
PFMT plus biofeedback over PFMT alone. The start date 
is 1 September 2013 and finish date 30 November 2018 
(figure 2).
trial groups
Participants in this trial will be randomly assigned to 
either PFMT or biofeedback-mediated PFMT. Alloca-
tion will be generated by a web-based programme devel-
oped and implemented by The Centre for Healthcare 
Randomised Trials (CHaRT), situated remotely from the 
trial office and recruiting centres.
Prior to randomisation, as part of the screening process, 
a visual and digital assessment of the woman’s vagina and 
pelvic floor muscles will be carried out to provide accu-
rate knowledge of the condition of the perineum and 
vagina (including areas of pain or increased tone), and 
the woman’s capacity for contracting and relaxing her 
pelvic floor muscles.
Control group (PFMt)
After randomisation, women will be taught by a trained 
therapist (nurse or physiotherapist) the correct exercise 
technique and this will be confirmed on digital palpation 
with the woman in the supine position. Women will be 
encouraged to become aware of the sensation or feeling 
Figure 1 OPAL study overview. PFMT, pelvic floor muscle training; UI, urinary incontinence.
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of contracting and holding the appropriate muscles, and 
also of relaxing them.
Women in the PFMT group will be offered six appoint-
ments with the trained therapist over a 16-week period at 
weeks 0, 1, 3, 6, 10 and 15. During these appointments, 
the PFMT programme will be delivered and home exer-
cise prescribed.
The initial PFMT programme will be identified and 
agreed between the individual woman and her therapist 
over the first and second appointment, according to the 
woman’s ability. The exercise programme will be prac-
tised during the appointments to allow the therapist to 
assess progress and adjust the programme as necessary. 
Home exercise will be prescribed after the first appoint-
ment, or as soon as the therapist confirms a correct tech-
nique has been achieved.
There are two main components to the PFMT protocol: 
resistance training and counterbracing (also called ‘The 
Knack’.17 Initial exercise prescription in terms of number 
and type of contractions, length of hold, number of 
sets, position, will be informed by the PERFECT (Power, 
Endurance, Repetitions, Fast, Every Contraction Timed) 
assessment.18 The starting dose comprises the number 
(and duration of hold) of near maximal contractions 
a woman is able to complete before the pelvic floor 
muscles reach fatigue. The programme is progressed (eg, 
increasing the number of repetitions by one, or dura-
tion of hold by one second, each week) according to 
the woman’s ability to reach her individualised goal. For 
example, a goal might be to exercise 3 days per week. On 
these days the women could aim for three exercise sets, 
with 3 min between sets. Each set could comprise 10 repe-
titions held for 10 s each, with 10 s rest between, followed 
by 10 fast contractions. Counterbracing is taught with a 
cough—a precontraction of the pelvic floor muscles to 
be held until the abdominal/diaphragmatic contrac-
tion ceases—and over time progressed to include other 
functional activities as clinically indicated. BCTs are built 
in to the PFMT protocol. The main categories of BCTs 
included are: beliefs, emotions and information; teaching 
and confirming PFM contraction, practising skills; goal 
setting; action planning; problem solving. A set of 30 
core BCTs are to be used if possible at each appointment 
(eg, agree and record PFMT action plan in new exercise 
diary), and a further set of 17 optional BCTs are to be 
used at the therapist’s discretion (eg, discuss pros and 
cons of doing PFMT). The use of the BCTs is recorded by 
therapists in a checklist.
No biofeedback equipment is used in the control 
group, although verbal feedback based on digital vaginal 
palpation is permitted.
Experimental group (PFMt plus EMG biofeedback)
The use of EMG biofeedback is included in the experi-
mental group in addition to all that is described above 
for the control group (both PFMT and BCT protocols). 
Figure 2 OPAL SPIRIT diagram. PFMT, pelvic floor muscle training; SPIRIT, Standard Protocol Items: Recommendations for 
Interventional Trials.
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Hand-held EMG biofeedback devices, which measure 
and monitor pelvic floor muscle contractions, are used 
to deliver biofeedback. The same type of device is used 
throughout the trial, both in clinic and at home.
Participants randomised to receive PFMT plus biofeed-
back will have a biofeedback protocol incorporated into 
their PFMT appointments, and will be given a biofeed-
back unit to use during home exercise sessions between 
appointments. The content of the biofeedback protocol is 
underpinned by the information-motivation-behavioural 
skills model of behaviour change,19 incorporating social 
cognitive theory,20 an evidence-based theory relating to 
self-efficacy and perseverance. It is hypothesised that 
self-efficacy for PFMT is enhanced because biofeedback 
offers information to women about a normally ‘hidden’ 
muscle activity. Biofeedback also supports motivation 
through providing audio and visual feedback (graphs 
on screen which can be printed off) on the ‘effort/
performance’ of the muscle contraction, which facilitates 
tracking changes in muscle strength and performance. In 
turn this enhances behavioural skills through improving 
the performance of a muscle contraction, and the timing 
of a contraction, to reduce leakage with increases in 
intra-abdominal pressure (eg, during cough, sneeze, lift). 
In this way the biofeedback ‘intensive’ trial group incor-
porates BCTs additional to those in the control group, 
that aim to enhance self-efficacy.
training in intervention delivery
All therapists delivering the trial interventions are clinical 
specialists or advanced practitioners already working in 
the area of continence and will receive training from the 
trial team on using the biofeedback units and associated 
software, implementing the PFMT, BCT and biofeedback 
protocols and completing the trial paperwork to ensure 
standardisation across centres. An intervention training 
manual will be provided to each centre covering details 
of the intervention development and delivery for both 
the control and experimental groups. Practical sessions 
using the biofeedback units will be incorporated into the 
training and there will be a forum for discussion with 
opportunities for questions. All centres will use the same 
model of biofeedback unit for clinic and home use.
data collection
Data will be collected via participant-completed ques-
tionnaires at baseline, 6, 12 and 24 months. In addition, 
at baseline women will record their leakage episodes in 
a 3-day bladder diary. During the 16-week intervention, 
women will complete a pelvic floor muscle exercise diary. 
At 6 months, women will have a blinded assessment of 
their pelvic floor muscles to quantify pelvic floor muscle 
function.
Regarding the data collection tools, the International 
Consultation on Incontinence Questionnaire-Urinary 
Incontinence Short Form (ICIQ-UI SF), the ICIQ-Fe-
male Lower Urinary Tract Symptoms (FLUTS), the ICIQ-
LUTSqol and the Pelvic Organ Prolapse Symptom Score 
(POP-SS) are instruments with evidence of reliability, 
validity and responsiveness. The Patient Global Impres-
sion of Improvement (PGI-I), the self-efficacy for PFMT 
scale and the EvQ-5D-3L have evidence of reliability and 
validity. The ICIQ Bowel Short Form used is an instrument 
not fully validated, but used because of its brevity and 
the lack of an alternative validated short bowel symptom 
questionnaire. The Oxford scale and International Conti-
nence Society (ICS) method of assessing pelvic floor func-
tion are standardised methods of digitally assessing the 
pelvic floor recognised by the International Continence 
Society. The remaining data are gathered via individual 
item questions focused on gathering specific informa-
tion, for example, relating to whether a participant has 
received any other treatment for UI, and what inconti-
nence products they have used.
Primary outcome measure
The severity of UI at 24 months is the primary outcome, 
as measured by the validated ICIQ-UI SF which encom-
passes urinary leakage frequency, amount and interfer-
ence with everyday life (total score 0–21, higher score 
indicates more severe UI).21
secondary outcomes measures
 ► Perceived improvement in UI (PGI-I).22
 ► Number with UI cured/improved (derived from the 
ICIQ-UI SF).21
 ► Uptake of surgery for UI.
 ► Uptake of other treatment for UI.
 ► Other lower urinary tract symptoms (eg, urgency, 
nocturia, pain, frequency) (ICIQ-FLUTS).23
 ► UI-specific quality of life (ICIQ-LUTSqol).24
 ► Prolapse symptoms (POP-SS).25
 ► Bowel symptoms (early version of ICIQ Bowel Short 
Form).
 ► Pelvic floor muscle function (Oxford scale,26 ICS 
method27).
 ► Self-efficacy for PFMT (PFME self-efficacy scale).28
 ► Adherence to prescribed PFMT programme (derived 
from pelvic floor muscle exercise diary/follow-up 
questionnaire).
 ► Cost and use of NHS services.
 ► Cost to the women and their families/carers.
 ► Incremental cost per quality-adjusted life-year 
(QALY; EQ-5D-3L).29
Centre selection
This trial will recruit from community, primary and 
secondary care settings across the UK. The first three 
centres will be identified and will start recruiting, 
providing an internal pilot. Experience of recruitment 
and data generated from these centres over 3 months will 
be used to fine-tune trial processes and protocols at new 
centres. Recruitment at other centres will be staggered 
with potentially more than 20 centres recruiting to the 
trial. Potential centres complete a feasibility question-
naire asking about: the number of women they could 
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recruit and how they would be identified; available staff, 
facilities and time to commit to the trial; previous experi-
ence of undertaking trials; any challenges and risks antic-
ipated. A selection will be made on this basis.
Participant selection
Women attending for a first continence appointment, 
or for a first outpatient appointment where UI is the 
presenting symptom, will be identified in advance from 
clinic lists in each centre, over the trial recruitment 
period. An OPAL Participant Information Leaflet will 
be given to potentially eligible women either before or 
at their routine appointment. When a woman attends 
for her appointment with her continence specialist they 
will confirm a clinical diagnosis of stress UI or mixed 
UI (those with urgency UI alone will be excluded), 
and assess other trial eligibility criteria by undertaking 
a vaginal examination as part of their routine care. If 
a woman is eligible and willing to take part, informed 
consent will be obtained by a member of the local 
research team.
Inclusion criteria
 ► Women 18 years of age or above, presenting with a 
new episode of stress or mixed UI, who are willing and 
suitable to be randomised.
Exclusion criteria
 ► Women who have urgency UI alone.
 ► Women who have had formal instruction in PFMT in 
the last year.
 ► Women who are unable to contract their pelvic floor 
muscles.
 ► Women who are pregnant or are less than 6 months 
postnatal.
 ► Women who have prolapse greater than stage II 
(>1 cm below the hymen on Valsalva).
 ► Women who are currently having treatment for pelvic 
cancer.
 ► Women who have cognitive impairment affecting 
capacity to give informed consent.
 ► Women who have neurological disease (multiple 
sclerosis, Parkinson’s disease, stroke, motor neuron 
disease, spinal injury).
 ► Women with a known nickel allergy or sensitivity.
 ► Women who are currently participating in other 
research relating to their UI.
randomisation
Women who are eligible and willing to take part will be 
randomised to either the experimental or control group 
via the automated computer randomisation application 
developed at the CHaRT, University of Aberdeen. The 
web-based application will be accessed by staff at the 
centre to determine the participant’s group. Allocation 
will be minimised on: type of UI (stress UI or mixed UI), 
centre, age (<50/≥50 years) and UI severity at baseline 
(ICIQ-UI SF score <13/≥13).30
Masking
Statistical analysis will be conducted by research staff 
with the group allocation masked, using study identity 
numbers only to identify women and questionnaires. 
Due to the nature of the interventions, group allocation 
cannot be concealed from the women, the therapists 
delivering the intervention or those entering data. The 
clinician undertaking 6-month pelvic floor muscle assess-
ments will not be aware of the woman’s group allocation.
data collection and management
Data collection and entry is managed by experienced 
staff at the OPAL Trial Office situated in Nursing, 
Midwifery and Allied Health Professions (NMAHP) 
Research Unit, Glasgow Caledonian University. Data are 
entered into the CHaRT web-based database. The final 
trial dataset will be accessed only by the trial statisticians 
and health economists. Trained therapists or research 
nurses at centres collect data on paper Case Report 
Forms at every participant appointment. Centre staff 
enter the screening and eligibility data directly onto the 
web-based database in order to randomise participants. 
Participants complete paper diaries throughout treat-
ment and outcome questionnaires at baseline, 6, 12 and 
24 months’ post-randomisation. Paper copies of case 
report forms, diaries and questionnaires are returned 
by post to the OPAL Trial Office to be entered onto the 
database. Copies of case report forms are also securely 
stored at each centre in accordance with local ethics 
protocols. Data from the longitudinal qualitative case 
study and process evaluation are gathered alongside 
and in addition to the main trial data and are described 
in the companion paper.
statistical analysis and sample size
All analyses will be according to the Statistical Analysis Plan 
and Health Economic Analysis Plan that will be agreed 
in advance with the Project Management Group (PMG) 
and the Trial Steering Committee (TSC). A single main 
analysis will be performed at the end of the trial when 
24-month follow-up has been completed. An indepen-
dent data monitoring and ethics committee (DMEC) will 
review confidential interim analyses of accumulating data 
at its discretion, at least annually. Analysis will be based 
on the intention-to-treat principle, such that women will 
be analysed in the groups to which they were allocated 
regardless of the intervention received.
The main effectiveness analysis will estimate the mean 
difference in the primary outcome (ICIQ-UI SF score) 
(and 95% CIs) between the experimental and control 
groups at 24 months using a general linear mixed model, 
adjusting for minimisation covariates, therapist type and 
baseline score. Centre and therapist type will be fitted, 
where possible, as random effects. Missing outcome 
data will be estimated using multiple imputation and 
included in a sensitivity analysis Secondary outcomes 
will be analysed in a similar manner using an appro-
priate generalised linear model. Complier average causal 
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effect analysis of the primary outcome will be conducted 
to investigate the impact of non-compliance. Subgroup 
analyses by type of incontinence (stress UI or mixed UI), 
type of therapist (physiotherapist or nurse), participant 
age (<50/≥50 years) and baseline UI severity (ICIQ-UI SF 
score <13/≥13) are also planned.
The primary economic outcome measure of cost effec-
tiveness is incremental cost per QALY at 24 months under-
taken from the NHS perspective. QALYs will be based on 
responses to the EQ-5D-3L30 and the ICIQ-LUTSqol.24 
Personal patient resource use data will be incorporated 
into the analysis to report on a wider perspective. Where 
appropriate the analysis of incremental costs, effective-
ness and cost-effectiveness will be based on similar statis-
tical models as those outlined in the statistical analysis 
section above. This 'within' trial analysis will include 
both deterministic and stochastic sensitivity analyses to 
explore statistical and other forms (eg, around unit costs 
or the source of utility estimates) of uncertainty. Similar 
subgroup analysis will be performed in the economic 
analysis as defined in the statistical analysis if deemed 
relevant. If relevant an economic model will be developed 
to provide additional information for policy-makers.
Assuming a clinically meaningful difference of 3 points 
on the ICIQ-UI SF score (eg, change from leaking urine 
‘once a day’ to ‘never’), which is similar to the minimal 
clinically important difference of 2.5 reported in a study 
of older women,31 and a conservative estimate for the 
SD of 10, a sample size of 234 per group would detect 
this difference (standardised effect size of 0.3) with 90% 
power at the 5% level of significance (two-sided alpha). 
Allowing for 22% drop out, we will randomise 300 women 
per group. With 600 subjects, we will also have 90% power 
to detect important differences in secondary outcomes.
safety measures
The OPAL trial involves treatments for UI which are well 
established in clinical practice, therefore adverse effects 
(although these are unlikely) will be those observed in 
everyday practice associated with the use of PFMT and 
biofeedback. In the OPAL trial, all serious adverse events 
experienced by a research participant will be reported to 
the main research ethics committee if they occur within 
30 days of the participant’s last PFMT appointment and 
where in the opinion of the Chief Investigator and/or the 
Chair of the DMEC the event is related and unexpected.
Patient involvement
Women with experience of UI are involved in the design, 
delivery and oversight of the trial through membership 
on the PMG and TSC. A lay summary of the findings will 
be sent to participants involved in the trial.
EthICs And dIssEMInAtIon
The trial will be conducted in accordance with the Inter-
national Conference on Harmonisation  Good Clin-
ical Practice (ICH GCP)) Note for Guidance on Good 
Clinical Practice. Trial safety and progress will be over-
seen by the independent DMEC and the TSC. Meetings 
of these committees will take place annually.
Final trial results will be disseminated to the funding 
body, the NIHR Health Technology Assessment 
Programme. The trial results will then be submitted 
to peer-reviewed international academic journals and 
presented at international conferences. Results will also 
contribute to the relevant Cochrane review. Participants 
will be provided with a summary of the results.
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